We hypothesised that if up-regulation of the PI3K/AKT pathway allowed Eμ-Myc/cRel−/− lymphomas to survive in the absence of CHK1, then targeting this pathway could be a good therapeutic strategy for tumours that have developed CHK1i resistance. This evidence concerns the gene MYC and lymphoma.